Effect of Ambroxol on the lung function, oxidative stress and inflammatory cytolines in AECOPD patients

• Main Authors: Kaisaier Aizezi, Xiaokaiti Maimaitiyimin, Xiao-Hong Yang
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-04-01
• Series: Journal of Hainan Medical University
• Subjects: Ambroxol; AECOPD; Lung function; Oxidative stress; Inflammatory factor
• Online Access: http://www.hnykdxxb.com/PDF/201608/8.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To explore the effect of Ambroxol on the lung function, oxidative stress and inflammatory factor in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: From February 2014 to August 2015, a total of 90 patients with AECOPD in our hospital were chosen as research objects and divided into observation group and control group according to their admission date with 45 cases in each group. All patients were given conventional treatment, and on this basis the observation group was given Ambroxol for 10 d. Before and after treatment, the lung function indicators (FVC, FEV1 and FEV1/FVC), the serum oxidative stress indicators (MDA and SOD) and the serum inflammatory factors (IL-6, IL-10 and TNF-α) were detected and compared, respectively. Results: After treatment, the lung function indicators FEV1, FVC and FEV1/FVC in observation group were (1.83 ± 0.25) L, (2.76 ± 0.21) L and (72.29 ± 5.10)%, respectively. Compared with before treatment and the post-treatment control group, they were significantly increased; after treatment, the oxidative stress indicator MDA in observation group was (4.24 ± 1.09) nmol/mL, while SOD was (82.20± 6.23) Nu/mL. Compared with before treatment and the post-treatment control group, the former was significantly reduced, while the latter was obviously increased; after treatment, the inflammatory factors IL-6 and TNF-α in the observation group were (5.15 ± 1.09) pg/mL and (3.35 ± 0.68) ng/L, respectively, while IL-10 was (7.22 ± 1.23) pg/L. Compared with before treatment and the post-treatment control group, the former two were apparently decreased, while the latter one was significantly grown. Conclusion: Ambroxol can obviously reduce the inflammatory response and significantly improve the oxidative stress and lung function in patients with AECOPD, which has positive significances in clinical.